LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

LLY

764.43

-0.25%↓

JNJ

153.41

0%↓

ABBV

187.23

-0.07%↓

NVO

72.52

+0.35%↑

UNH

295.54

-1.64%↓

Search

Anavex Life Sciences Corp

Open

SectorHealthcare

7.78 0.91

Overview

Share price change

24h

Current

Min

7.59

Max

7.83

Key metrics

By Trading Economics

Income

915K

-11M

EPS

-0.132

Employees

42

EBITDA

-779K

-13M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+269.17% upside

Dividends

By Dow Jones

Next Earnings

5 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-58M

669M

Previous open

6.87

Previous close

7.78

News Sentiment

By Acuity

50%

50%

174 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Anavex Life Sciences Corp Chart

Past performance is not a reliable indicator of future results.

Related News

4 Jun 2025, 17:05 UTC

Acquisitions, Mergers, Takeovers

UniCredit's $10 Billion-Plus Bid for Banco BPM Gets EU Clearance

4 Jun 2025, 23:45 UTC

Market Talk

Nikkei May Fall on Signs of Weakness in U.S. Economy -- Market Talk

4 Jun 2025, 23:45 UTC

Market Talk

Gold Steady, Underpinned by Weak U.S. Economic Data -- Market Talk

4 Jun 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Gran Tierra Energy: To Sell Wholly Owned Subsidiary Gran Tierra North Sea Limited to NEO Energy for $7.5M >GTE.T

4 Jun 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Gran Tierra Energy: Transaction Is Expected to Close in 3Q >GTE.T

4 Jun 2025, 21:36 UTC

Acquisitions, Mergers, Takeovers

Gran Tierra Energy: NEO Energy Is a Private Upstream Co and Independent Operator in the United Kingdom Continental Shelf >GTE.T

4 Jun 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

New MicroStrategy Preferred, a Bitcoin Play, Should Yield 10% or More -- Barrons.com

4 Jun 2025, 20:44 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications: Approvals Received From Canadian Football League, Major League Soccer

4 Jun 2025, 20:44 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications: Approval Received From American Hockey League

4 Jun 2025, 20:43 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications: Approvals Received From National Hockey League, National Basketball Association

4 Jun 2025, 20:42 UTC

Acquisitions, Mergers, Takeovers

Rogers Communications Gets League Approvals to Buy Bell's 37.5% Stake in Maple Leaf Sports & Entertainment >RCI.A.T

4 Jun 2025, 20:37 UTC

Earnings

These Stocks Moved the Most Today: Broadcom, Tesla, Dollar Tree, ON Semi, CrowdStrike, Guidewire, Asana, and More -- Barrons.com

4 Jun 2025, 20:34 UTC

Market Talk

Starbucks Names COO -- Market Talk

4 Jun 2025, 20:23 UTC

Acquisitions, Mergers, Takeovers

Transocean Move Will Contribute Approximately $100 M in Backlog, Excluding Additional Services >RIG

4 Jun 2025, 20:23 UTC

Acquisitions, Mergers, Takeovers

Transocean Program Expected to Commence in the 1Q in Direct Continuation of the Rig's Current Program >RIG

4 Jun 2025, 20:22 UTC

Acquisitions, Mergers, Takeovers

Transocean Two-well Option Was Exercised for the Transocean Spitsbergen in Norway >RIG

4 Jun 2025, 19:06 UTC

Market Talk

Oil Futures Settle Lower in Choppy Trade -- Market Talk

4 Jun 2025, 19:04 UTC

Market Talk

U.S. Natural Gas Ends Flat Ahead of Storage Data -- Market Talk

4 Jun 2025, 18:48 UTC

Market Talk

Gold Turns Higher on Increased Uncertainty -- Market Talk

4 Jun 2025, 18:42 UTC

Earnings

These Stocks Are Moving the Most Today: Broadcom, Tesla, Dollar Tree, ON Semi, CrowdStrike, Guidewire, Asana, and More -- Barrons.com

4 Jun 2025, 17:48 UTC

Market Talk

Oil Futures Down Despite Big U.S. Crude Stock Draw -- Market Talk

4 Jun 2025, 17:41 UTC

Market Talk

Bank of Canada Made 'Foolhardy' Attempt to Play Down Economic Weakness -- Market Talk

4 Jun 2025, 16:50 UTC

Market Talk

CVS Seen as Biggest Beneficiary of Rite Aid Closures -- Market Talk

4 Jun 2025, 16:48 UTC

Market Talk

End of U.S. Exceptionalism Bodes Well for Carry Trade -- Market Talk

4 Jun 2025, 16:37 UTC

Acquisitions, Mergers, Takeovers

UniCredit: Transaction Will Be Authorized

4 Jun 2025, 16:37 UTC

Acquisitions, Mergers, Takeovers

UniCredit: European Commission Won't Initiate In-Depth Investigation

4 Jun 2025, 16:35 UTC

Acquisitions, Mergers, Takeovers

UniCredit Received EU Letter on Closure of Preliminary Review of Banco BPM Deal

4 Jun 2025, 16:32 UTC

Market Talk

BOC's Macklem Highlights Economy's 'Resilience' to Tariffs -- Market Talk

4 Jun 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 Jun 2025, 15:57 UTC

Market Talk

Gold Futures Rise on Persistent Market Nerves -- Market Talk

Peer Comparison

Price change

Anavex Life Sciences Corp Forecast

Price Target

By TipRanks

269.17% upside

12 Months Forecast

Average 28.5 USD  269.17%

High 42 USD

Low 15 USD

Based on 2 Wall Street analysts offering 12 month price targets forAnavex Life Sciences Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

2

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

8.275 / 9.312Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

174 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Interest expense on debt

EBITDA

Operating profit

$

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.